CELLECTAR BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

ITEM 7.01 REGULATION FD DISCLOSURE

On January 6, 2020, we issued a press release announcing that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to CLR 131 in Lymphoplasmacytic Lymphoma (LPL). A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits



 Number    Title
  99.1       Press release dated January 6, 2020, titled "Cellectar Receives Orphan
           Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)"




  2

© Edgar Online, source Glimpses